These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26914831)

  • 1. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
    Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
    PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
    Miura Y; Imamura CK; Fukunaga K; Katsuyama Y; Suyama K; Okaneya T; Mushiroda T; Ando Y; Takano T; Tanigawara Y
    BMC Cancer; 2014 Dec; 14():964. PubMed ID: 25515134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
    Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
    Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
    Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
    Mizuno T; Terada T; Kamba T; Fukudo M; Katsura T; Nakamura E; Ogawa O; Inui K
    Ann Oncol; 2010 Jun; 21(6):1382-1383. PubMed ID: 20348146
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
    Watanabe A; Yamamoto K; Ioroi T; Hirata S; Harada K; Miyake H; Fujisawa M; Nakagawa T; Yano I; Hirai M
    Biol Pharm Bull; 2017; 40(4):458-464. PubMed ID: 28381801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
    Mizuno T; Fukudo M; Fukuda T; Terada T; Dong M; Kamba T; Yamasaki T; Ogawa O; Katsura T; Inui K; Vinks AA; Matsubara K
    Ther Drug Monit; 2014 Jun; 36(3):310-6. PubMed ID: 24825438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
    Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
    Narjoz C; Cessot A; Thomas-Schoemann A; Golmard JL; Huillard O; Boudou-Rouquette P; Behouche A; Taieb F; Durand JP; Dauphin A; Coriat R; Vidal M; Tod M; Alexandre J; Loriot MA; Goldwasser F; Blanchet B
    Invest New Drugs; 2015 Feb; 33(1):257-68. PubMed ID: 25344452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
    Numakura K; Tsuchiya N; Kagaya H; Takahashi M; Tsuruta H; Inoue T; Narita S; Huang M; Satoh S; Niioka T; Miura M; Habuchi T
    Anticancer Drugs; 2017 Jan; 28(1):97-103. PubMed ID: 27564227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
    Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
    PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
    Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
    Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
    Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
    Teo YL; Wee HL; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
    Pharmacogenomics J; 2016 Feb; 16(1):47-53. PubMed ID: 25778465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
    Noda S; Otsuji T; Baba M; Yoshida T; Kageyama S; Okamoto K; Okada Y; Kawauchi A; Onishi H; Hira D; Morita SY; Terada T
    Clin Genitourin Cancer; 2015 Aug; 13(4):350-358. PubMed ID: 25701374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.
    Kato R; Kato Y; Matsuura T; Kanehira M; Takata R; Obara W
    BMC Cancer; 2017 Mar; 17(1):214. PubMed ID: 28335742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
    Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY
    Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.
    Kato H; Sassa N; Miyazaki M; Takeuchi M; Asai M; Iwai A; Noda Y; Gotoh M; Yamada K
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):855-62. PubMed ID: 27586968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.